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Open Access

Identification of factors associated with good
response to growth hormone therapy in children
with short stature: results from the ANSWER
Program®
Peter A Lee1*, John Germak2, Robert Gut2, Naum Khutoryansky2 and Judith Ross3

Abstract
Objective: To identify factors associated with growth in children on growth hormone (GH) therapy using data
from the American Norditropin Studies: Web-enabled Research (ANSWER) Program® registry.
Methods: GH-naïve children with GH deficiency, multiple pituitary hormone deficiency, idiopathic short stature,
Turner syndrome, or a history of small for gestational age were eligible (N = 1,002). Using a longitudinal statistical
approach, predictive factors were identified in patients with GHD for change from baseline in height standard
deviation score (ΔHSDS) following 2 years of treatment.
Results: Gradual increases in ΔHSDS over time were observed for all diagnostic categories. Significant predictive
factors of ΔHSDS, ranked by significance were: height velocity (HV) at 4 months > baseline age > baseline HSDS >
baseline body mass index (BMI) SDS > baseline insulin-like growth factor I (IGF-I) SDS; gender was not significant.
HV at 4 months and baseline BMI SDS were positively correlated, whereas baseline age, HSDS, and IGF-I SDS were
negatively correlated with ΔHSDS.
Conclusions: These results may help guide GH therapy based on pretreatment characteristics and early growth
response.

Introduction
Treatment with exogenous growth hormone (GH) has
become a well-accepted therapeutic option for children
with growth failure. Since the availability of recombinant
human GH (rhGH) in 1985, a wide range of conditions
associated with decreased growth, including GH deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), children born small for gestational age
(SGA), Prader-Willi syndrome (PWS), idiopathic short
stature (ISS), and SHOX (short stature homeobox) gene
haploinsufficiency have been approved by the United
States Food and Drug Administration (FDA) for treatment [1-4].
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Treatment with GH has been demonstrated to
increase both short-term growth and adult height in
pediatric patients with a variety of different growth disorders [5-8]. However, considerable variability in
response to this treatment has been reported across and
within different diagnostic categories [9-11]. Such variability makes decisions about whether to treat with GH,
when to begin treatment, and what dosing to use more
difficult [12].
Reports from clinical trials and analyses suggest multiple factors that influence the response to GH treatment.
Variables associated with better responses to GH treatment in patients with ISS include first-year growth
response, younger age at start of treatment, the difference in height at the start of treatment from target
height SD score (HSDS), and GH dose [13,14]. Additional factors may include underlying genetic conditions,
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presence of concomitant illness, and compliance with
treatment [15].
Formal height prediction models have been developed
that combine information regarding patient- and treatment-related factors. Such prediction models of
response to GH have been developed for patients with
isolated or idiopathic GHD [16-20], SGA [21-23],
chronic kidney disease [24], ISS [25], and TS [26]. These
models have the potential to aid individualized GH
treatment planning and the adjustment of therapy based
on early responses [27]. However, even though GH
treatment regimens can be based on model-derived predictions of growth response [28], existing models
account for only about one-half of the variability in the
response to GH. Addition of genetic, biochemical, and
other new variables to existing models may improve
their accuracy and clinical utility [29,30].
Since 2002, the ANSWER (American Norditropin Studies: Web-enabled Research) Program® registry has collected information on patients receiving Norditropin.
Participation within the ANSWER Program is at the discretion of the participating physicians and includes diagnostic categories in which treatment with growth
hormone is used. The aim of this paper is to report
growth response among different diagnostic categories
and to identify factors associated with greater growth
response over the first 2 years in children with GHD
undergoing treatment with GH.

calculated according to the standard formulas provided
by the Center for Disease Control and Prevention [32].
IGF-I SDS scores were calculated using a standard algorithm and reference values provided by Diagnostic Systems Laboratories, Inc. (Webster, TX, USA). Data were
collected at baseline and at 4 months, 1 year, and 2
years of GH treatment. Data at 4 months were collected
within a 1-month window and data at 1 and 2 years
were collected within a 3-month window. To eliminate
the potential of erroneous data having been entered, the
following rules were used to remove patients from the
analysis: lack of height information at baseline, 4
months, 1 year, or 2 years; baseline age 0 or > 18 years;
baseline HSDS less than -5 or greater than +2; and baseline height < 35 cm or > 200 cm. Also, patients were
excluded when key variables from baseline or subsequent values were deemed physically or chronologically
implausible (3.77% of potential subjects were excluded
according to this criteria).

Methods
Answer program registry

Data for this analysis were obtained from the ANSWER
Program registry, a collection of long-term efficacy and
safety information from patients treated with Norditropin® (somatropin [rDNA origin] injection, Novo Nordisk A/S, Denmark) [31] in the United States. Patient
histories and physical examination data were entered by
participating physician investigators using the ANSWER
Program registry reporting form, a web-based data entry
tool. Informed consent was obtained in all cases. While
the registry enrolls GH-treatment-naïve and non-naïve
patients, for the purpose of this analysis, only naïve
patient data from the following diagnostic categories
were included in the current analyses: 1) GHD (isolated/
idiopathic), 2) multiple pituitary hormone deficiency
(MPHD), 3) TS, 4) SGA, and 5) ISS.
Study description

Patient data collected at the first visit and/or follow-up
visits included age, gender, GH dose, HSDS, insulin-like
growth factor-I (IGF-I) SDS, body mass index (BMI)
SDS, bone age, and annualized height velocity (HV).
The maximal stimulated serum GH concentration was
also recorded. Height and BMI SDS (z scores) were

Regression model development

In this study, a longitudinal statistical approach was
used to identify factors that have significant predictive
value for change in HSDS from baseline (ΔHSDS) in a
regression model. ΔHSDS data collected following the
first and second years of treatment were included in the
model. A smoothing procedure was applied for the corresponding mean value curves for first-year HV and
baseline age. Due to the limited number of patients in
the MPHD, TS, SGA, and ISS diagnostic categories,
regression analysis was only performed for patients with
GHD. The curves presented were built using polynomial
regression. The quadratic polynomial regression, under
the assumption that the height SD is not a function of
baseline age, provided a sufficient fitting, while higher
terms (for example, cubic and fourth degree) were not
statistically significant.

Results
Baseline demographics

The ANSWER Program registry (as of November 30,
2009) contained information for over 9,000 patients, of
which 1,002 GH treatment-naïve patients from selected
diagnostic categories (GHD, MPHD, TS, SGA, and ISS)
met the criteria for inclusion in this analysis. Baseline
demographic characteristics for the subjects in this
study by specific diagnostic category are summarized in
Table 1. The study included longitudinal data for 698
patients with GHD, 71 with MPHD, 60 with TS, 50
with SGA, and 123 with ISS. Mean baseline ages were
lower for MPHD (6.4 years), SGA (7.1 years), and TS
(8.5 years) groups compared to those for GHD (10.9
years) or ISS (11.2 years). Baseline mean peak GH levels
were lowest for patients with GHD and MPHD (5.5 and
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Table 1 Baseline demographics by diagnostic category
GHD

MPHD

Turner
n

SGA

Mean (SD)

n

ISS

n

Mean (SD)

n

Mean (SD)

Mean (SD)

n

Mean (SD)

Male

543

-

53

-

0

-

33

-

91

-

Female

155

-

18

-

60

-

17

-

32

-

Age

698

10.9 (3.46)

71

6.4 (5.23)

60

8.5 (4.17)

50

7.1 (3.41)

123

11.2 (2.88)

HSDS

698

-2.2 (0.86)

71

-2.0 (1.36)

60

-2.5 (0.77)

50

-2.8 (0.97)

123

-2.3 (0.68)

IGF-I SDS

605

-2.5 (1.26)

31

-3.2 (1.54)

34

-2.0 (1.43)

32

-2.1 (1.53)

114

-2.2 (1.11)

BMI SDS
Bone Age, yrs

681
616

-0.1 (1.38)
9.4 (3.31)

49
39

0.5 (1.84)
8.0 (4.58)

55
43

0.5 (0.97)
7.8 (3.45)

49
44

-0.8 (1.35)
6.1 (3.36)

123
115

-0.8 (3.38)
9.7 (2.93)

Gender

Peak GH, ng/mL

606

5.5 (2.69)

40

3.6 (3.03)

5

12.5 (8.25)

17

13.8 (10.95)

97

15.2 (8.10)

GH dose, μg/kg/day

697

45.9 (10.1)

71

40.6 (11.2)

60

51.9 (9.0)

50

49.9 (13.5)

123

46.1 (8.6)

BMI, body mass index; GH, growth hormone; GHD, growth hormone deficiency; HSDS, height standard deviation score; IGF-I, insulin-like growth factor I; ISS,
idiopathic short stature; MPHD, multiple pituitary hormone deficiency; SD, standard deviation; SDS, standard deviation score; SGA, small for gestational age

3.6 ng/mL, respectively). Baseline mean GH dose (μg/
kg/day) for the different diagnostic categories was the
lowest for MPHD patients, consistent with their apparently greater degree of GH deficiency and associated
GH sensitivity. For all diagnostic categories, the mean
and median GH dose did not increase more than 0.007
mg/kg/day over the two years, indicating a very narrow
GH dose change over this period.
Height outcomes

The effects of GH treatment on ΔHSDS over 2 years of
treatment are shown in Table 2. Gradual increases in
ΔHSDS were observed over time and ranged between
0.15 (ISS) to 0.37 (MPHD) at 4 months, and 0.82 (TS)
to 1.20 (MPHD) at 2 years, with the largest ΔHSDS
observed at year 1 and year 2 in patients with MPHD
and SGA. Annualized HV at 4 months was 13.6 cm/year
for MPHD, and between 8.33 (TS) and 9.96 (SGA) cm/
year for the other indications (Figure 1). Within each
diagnostic category, mean annualized HV was the
greater during the first year, and generally decreased
during the second year. Mean annualized HV at 1 year
was greatest for MPHD at 10.74 cm/year, and ranged
between 7.97 (TS) and 9.57 (GHD) for the other
indications.

baseline age, HSDS, and IGF-I SDS were negatively correlated with ΔHSDS. Gender was less influential than
the above factors (Table 3) and was not detected as statistically significant in this analysis.

Table 2 HSDS and ΔHSDS by diagnostic category
Mean (SD)

n

Mean (SD)

Baseline
4 Months

698
698

-2.22 (0.86)
-2.03 (0.82)

698

0.19 (0.33)

Year 1

698

-1.61 (0.83)

698

0.61 (0.49)

Year 2

697

-1.17 (0.88)

697

1.06 (0.64)

Baseline

71

-1.98 (1.36)

-

-

4 Months

70

-1.62 (1.30)

70

0.37 (0.68)

Year 1

70

-1.13 (1.04)

70

0.85 (0.76)

Year 2
Turner

70

-0.79 (1.04)

70

1.20 (1.04)

Baseline

60

-2.49 (0.77)

-

-

4 Months

59

-2.32 (0.82)

59

0.18 (0.20)

Year 1

60

-1.99 (0.86)

60

0.50 (0.31)

Year 2

60

-1.68 (0.90)

60

0.82 (0.43)

Baseline

50

-2.76 (0.97)

-

-

4 Months
Year 1

50
50

-2.48 (0.88)
-1.96 (0.93)

50
50

0.28 (0.47)
0.80 (0.59)

Year 2

50

-1.59 (1.00)

50

1.18 (0.65)

Baseline

123

-2.31 (0.68)

-

-

4 Months

123

-2.16 (0.69)

123

0.15 (0.19)

Year 1

123

-1.77 (0.69)

123

0.54 (0.38)

Year 2

123

-1.41 (0.79)

123

0.90 (0.59)

GHD

MPHD

SGA

Regression analysis

Linear regression was performed on HSDS data for
patients with GHD (Table 3). Variables significantly
associated with ΔHSDS 1 and 2 years included HV at 4
months, and baseline age, HSDS, BMI SDS, and IGF-I
SDS. The ranking of importance of predictive factors as
related to ΔHSDS (as determined by the F value, the
higher the more influential) was as follows: HV at 4
months > baseline age > baseline HSDS > baseline BMI
SDS > baseline IGF-I SDS. HV at 4 months and baseline
BMI SDS were positively correlated with ΔHSDS, while

ΔHSDS

HSDS
n

ISS

GHD, growth hormone deficiency; HSDS, height standard deviation score; ISS,
idiopathic short stature; MPHD, multiple pituitary hormone deficiency; SD,
standard deviation; SGA, small for gestational age.

Lee et al. International Journal of Pediatric Endocrinology 2011, 2011:6
http://www.ijpeonline.com/content/2011/1/6

Page 4 of 7

Mean Height Velocity

16

4 months

14

Year 1

Year 2

12
10
8
6
4
2
0

GHD

MPHD

n = 681 697 694

69

71

TS

71

59

59

SGA
59

49

50

ISS
50

118 123 122

Figure 1 Height velocity for all diagnostic categories over time.

Analysis of the mean values was used to build
smoothed curves for demonstration of the relationship
between first-year ΔHSDS and baseline age (Figure 2A
and 2B), and between first-year HV and baseline age (Figure 2C and 2D) in male and female patients with GHD.
Generally, the curves demonstrate that younger baseline
age is associated with greater ΔHSDS and HV in these
patients. Similar curves were observed with male and
female patients for both ΔHSDS and first-year HV.

Discussion
In this longitudinal study of GH treatment in patients
with GHD, MPHD, TS, SGA, and ISS, HSDS improved
over time. For patients with GHD, several variables were
identified that correlated with growth response during
the first and second years of GH treatment. HV at 4
Table 3 Regression model for longitudinal ΔHSDS at year
1 and year 2 for patients with GHD (n = 698).
b Estimate

F Value

Height velocity at 4 months

0.0319

214.31

< .0001

Baseline age

-0.0439

74.17

< .0001

Baseline HSDS

-0.0776

29.11

< .0001

Baseline BMI SDS

0.0398

20.62

< .0001

Baseline IGF-I SDS

-0.0245

5.74

.0169

Gender

-0.0438

2.46

.1175

Characteristic

P Value

BMI, body mass index; GHD, growth hormone deficiency; HSDS, height
standard deviation score; IGF-I, insulin-like growth factor I; SDS, standard
deviation score.

months was the most significant predictor of ΔHSDS
observed in the first 2 years of GH treatment. This
observation that 4-month HV was such a strong predictor is a novel finding, since many studies do not consistently report growth this early in the treatment cycle.
Additional factors that were influential in predicting
HSDS outcomes were ranked in order of importance:
younger baseline age > lower baseline HSDS > higher
baseline BMI SDS > lower baseline IGF-I SDS.
For the GHD patient population, age and baseline
HSDS were important determinants of the response to
GH treatment, as previously demonstrated [18,20].
However, other reports have also indicated additional
significant factors, such as birth weight SDS and GH
dose [20]. The present results also indicated that higher
baseline BMI was positively correlated with the growth
response to GH for patients with GHD. Birth weight
SDS and weight SDS were shown to be correlated with
growth response to GH in the Pharmacia Kabi International Growth Study, suggesting that the heavier the
child was, the greater the expected growth response to
GH treatment [20]. The impact of BMI in this study
might reflect, at least in part, the importance of nutrition for optimization of outcomes in patients receiving
GH [1,33].
In general, the results from this analysis are consistent
with previously published results for specific patient
populations. A prior prediction study in patients with
TS indicated that first-year growth response to GH was
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B.
GHD Female

First-Year Change in Height SDS

GHD Male
3

3

2

2

1

1

0

0

–1

–1
0

1

2

3

4

5

6

7

8

9

10

11

12

13 14

15

16

17

18

0

1

2

3

4

5

6

7

Age at Baseline
Mean

Mean + SD

Mean – SD

Mean

C.

9

10

11

Mean + SD

12

13 14

15

16

17

18

Mean – SD

D.
GHD Male

First-Year Height Velocity

8

Age at Baseline

GHD Female

24

24

21

21

18

18

15

15

12

12

9

9

6

6

3

3

0

0
0

1

2

3

4

5

6

7

8

9

10

11

12

13 14

15

16

17

18

0

1

2

3

4

5

Age at Baseline
Mean

Mean + SD

6

7

8

9

10

11

12

13 14

15

16

17

18

Age at Baseline
Mean – SD

Mean

Mean + SD

Mean – SD

Figure 2 First-year change from baseline HSDS and height velocity vs baseline age for patients with GHD (A, Change in baseline
HSDS in male patients with GHD; B, Change in baseline HSDS in female patients with GHD; C, Change in height velocity in male
patients with GHD; D, Change in height velocity in female patients with GHD).

significantly influenced by weekly GH dose, chronological age, HSDS, body weight SDS, number of GH injections per week, and adjunctive oxandrolone treatment
[26]. Predictors of the growth response over a longer
duration of treatment (2-4 years) included HV during
previous years, weekly GH dose, weight SDS, age, and
oxandrolone treatment [26]. In SGA patients, results
from one study found that first-year growth response to
GH treatment was the most important predictor of second-year growth response [21]. Other variables that
were significantly correlated with the growth response
to GH included GH dose, weight and age at the start of
treatment, and midparental HSDS [21]. Studies in the
ISS patient population have identified additional factors
as predictors of longer-term responses to GH, including
baseline HSDS, GH dose, weight at the start of treatment, and first-year growth response [13,14]. It is
important to recognize that this category may be the
most heterogenous, with growth failure being a consequence of many different etiologies.
Specific results from other studies that are consistent
with the present analysis, include the lack of gender
effect on response to GH treatment. Analysis of results
from the Pfizer Kabi International Growth Study database found no significant gender-related differences in

effects of GH in HV or HSDS over 2 or 3 years of treatment [34]. In 8,018 patients with ISS in the National
Cooperative Growth Study there was no significant
effect of gender on first-year HV or first-year change
from baseline in height SDS [35]. In a recent report, a
large cohort of male and female patients with GHD,
MPHD, TS, SGA, NS, and ISS from the ANSWER Program registry was used to assess gender-related differences in ΔHSDS following 2 years of GH treatment.
Results demonstrated increased ΔHSDS in all patients,
however, clinically relevant gender differences were not
observed [36]. The importance of early timing for initiation of treatment from the present analysis is also consistent with previous findings. A National Registry of
Growth Hormone Treatment report in the Netherlands
that included 342 patients (diagnosis of GHD or a maximal GH response during provocation tests of less than
11 ng/mL) indicated that initiation of treatment before
puberty resulted in a change from baseline in HSDS of
0.71 vs 0.58 for those who initiated treatment after puberty [19]. Results from the French registry of 2,852
patients with idiopathic GHD also indicated that prepubertal initiation of GH treatment was associated with
significantly greater adult height gain [37]. Although in
this study it is not known what proportion of patients
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across the different diagnostic categories may have been
in puberty, the mean baseline chronological and bone
ages are consistent with the majority of patients being
prepubertal, and this likely lessens the impact of puberty
on the observed growth responses.
The different correlations between baseline age, HSDS,
BMI SDS, and IGF-I SDS, with growth response over 2
years of treatment with GH, carry implications for clinical practice. The correlation of baseline age with
ΔHSDS and HV in the patients with GHD further support the initiation of GH at as young an age as possible
to promote optimal growth. This concept is supported
by results from another study that demonstrated a relationship between baseline age and first-year HV for
patients with GHD, MPHD, and TS [15]. Several consensus statements endorse the use of GH treatment as
soon as a diagnosis is made or growth failure is demonstrated for patients from several diagnostic categories
[38-41]. The inverse relationship observed between baseline IGF-I and the two-year change in HSDS is consistent with an increased sensitivity to the effects of GH in
patients who have a greater degree of GHD. In this
non-interventional observational study, serum IGF-I was
measured at a number of commercial laboratories
reflecting routine clinical practice. IGF-I SDS was calculated using one formula which provided consistency to
the analysis. This is also reflected in the finding that
mean baseline IGF-I SDS in both the GHD and MPHD
populations was lower than that observed in non-GHD
patients. The positive correlation observed between
baseline BMI SDS and ΔHSDS may emphasize the
importance of nutrition in patients with growth failure
[33,40]. An abnormally low BMI in pediatric patients
may be a sign of malnutrition, which can also be associated with growth disturbances. In the end, the role of
baseline age, HSDS, BMI SDS, and IGF-I SDS in the
response of individual patients to GH therapy should all
be considered for optimal management of short stature
or growth failure.

Conclusion
The present results from a large patient cohort enrolled
in the ANSWER Program registry demonstrate gradual
increases in ΔHSDS over time for all diagnostic categories. For patients with GHD, greater HV at 4 months
is the most significant predictor of ΔHSDS over the first
2 years of GH treatment, while gender did not have any
influence.
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